Oil-in-water composition for the second component of a topical body correction film-forming agent.

Abstract

The present invention provides a second agent for a coating-type body corrective film-forming agent that can shorten the crosslinking reaction time in film formation and improve the durability of the resulting film. [Solution] The oil-in-water composition of the present disclosure comprises a dispersion medium containing water and oil droplets dispersed in the dispersion medium, the oil droplets containing oil and a catalyst as a crosslinking component, and is used as the second agent of a coating-type body correcting film-forming agent comprising a first agent containing a crosslinking reactive component that constitutes a body correcting film and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component.

Description

[Technical Field]

[0001] This disclosure relates to an oil-in-water composition for the second component of a coating-type body corrective film-forming agent. [Background technology]

[0002] There are known topical film-forming agents that can be applied to the body surface to form a film that protects the skin while correcting wrinkles, scars, and other imperfections.

[0003] Patent Document 1 discloses a formulation for application to the skin, comprising: a) (i) a reactive element comprising at least one high-viscosity vinyl-terminated organopolysiloxane having a viscosity of 100,000 to 500,000 cst or cP at 25°C, at least one low-viscosity vinyl-terminated organopolysiloxane having a viscosity of 500 to 50,000 cst or cP at 25°C, and at least one hydride-functionalized polysiloxane; and (ii) a reactive reinforcing component comprising a reinforcing element; and b) a crosslinking component comprising a platinum catalyst; wherein the crosslinking component promotes the crosslinking of the reactive reinforcing component in situ, resulting in the formation of a film on the skin. [Prior art documents] [Patent Documents]

[0004] [Patent Document 1] Patent No. 6105468 [Overview of the project] [Problems that the invention aims to solve]

[0005] The technology described in Patent Document 1 is a technique in which a first agent containing reactive elements such as vinyl-terminated organopolysiloxane is applied to the skin to form a first agent layer, and then a second agent containing a platinum catalyst is applied to the first agent layer to crosslink the reactive elements in the first agent layer and form a film on the skin.

[0006] The film formed by this technology is created by a cross-linking reaction between the cross-linking reactive elements in the first agent applied to the skin and the catalyst in the second agent, and therefore requires a certain cross-linking reaction time. If the cross-linking reaction time is long, users may experience stress during the preparation of the film, and there is a risk that problems such as tearing of the film may occur if the film is touched while it is still uncross-linked. Therefore, it was desirable to shorten the cross-linking reaction time for this technology.

[0007] Furthermore, since the coating formed by such technology is typically located on the outermost surface of the body and exposed to the external environment, there was a desire for further improvement in the durability of the coating.

[0008] Therefore, the subject of this disclosure is to provide a second agent for a coating-type body corrective film-forming agent that can shorten the crosslinking reaction time in film formation and improve the durability of the resulting film. [Means for solving the problem]

[0009] <Aspect 1> A dispersion medium containing water, and Oil droplets dispersed in the aforementioned dispersion medium An oil-in-water composition comprising, The oil droplets contain oil and a catalyst as a crosslinking component. Used as the second agent in a coating-type body corrective film-forming agent, comprising a first agent containing a crosslinking reactive component that constitutes a body corrective film and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component, Oil-in-water composition. <Aspect 2> The composition according to embodiment 1, wherein the oil component comprises a first unsaturated organopolysiloxane or a first hydride-functionalized polysiloxane. <Aspect 3> The composition according to embodiment 1 or 2, wherein the blending ratio of the catalyst to the oil is 0.060% or more, provided that in the calculation of the blending ratio, if the oil contains the first unsaturated organopolysiloxane or the first hydride-functionalized polysiloxane, the first unsaturated organopolysiloxane and the first hydride-functionalized polysiloxane are excluded from the oil. <Aspect 4> A composition according to any one of embodiments 1 to 3, comprising at least one emulsifier selected from the group consisting of hydrocarbon surfactants, silicone surfactants, and amphiphilic powders. <Aspect 5> A composition according to any one of embodiments 1 to 3, comprising at least one emulsifier selected from the group consisting of polyoxyethylene alkyl ether, polyoxyethylene steryl ether, polyoxyethylene fatty acid ester, polyoxyethylene polyhydric alcohol fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, glycol fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, polyglycerin fatty acid ester, polyether-modified silicone, alkyl-comodified polyether-modified silicone, and amphiphilic powder. <Pattern 6> The composition according to embodiment 4 or 5, wherein the amount of the emulsifier is 5% by mass or less relative to the total amount of the oil-in-water composition. <Aspect 7> A composition according to any one of embodiments 1 to 6, comprising a polymer emulsifier. <Aspect 8> The compositional agent according to embodiment 7, wherein the polymer emulsifier is at least one selected from the group consisting of (acrylates / alkyl(C10-30) acrylate) crosspolymer, (ammonium acryloyldimethyltaurate / beheneth-25 methacrylate) crosspolymer, (hydroxyethyl acrylate / sodium acryloyldimethyltaurate) copolymer, PEG-modified crosspolymer / copolymer siloxane, polyether-modified crosspolymer / copolymer siloxane, stearoxyhydroxypropyl methylcellulose, and polyoxyethylene. <Aspect 9> The composition according to embodiment 7 or 8, wherein the amount of the polymer emulsifier is 2% by mass or less relative to the total amount of the oil-in-water composition. <Aspect 10> The composition according to any one of embodiments 1 to 9, wherein the catalyst is at least one selected from the group consisting of platinum carbonylcyclovinylmethylsiloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethylsiloxane complex, and platinum octanealdehyde / octanol complex. <Aspect 11> A topical body corrective film-forming agent comprising a first agent and a second agent, The first agent comprises at least one selected from the group consisting of a second unsaturated organopolysiloxane and a second hydride-functionalized polysiloxane. The second agent is an oil-in-water composition according to any one of embodiments 1 to 10, If the first agent comprises only the second unsaturated organopolysiloxane among the second unsaturated organopolysiloxane and the second hydride-functionalized polysiloxane, then the second agent comprises the first hydride-functionalized polysiloxane. If the first agent comprises only the second hydride-functionalized polysiloxane among the second unsaturated organopolysiloxane and the second hydride-functionalized polysiloxane, then the second agent comprises the first unsaturated organopolysiloxane. A topical body correction film-forming agent. <Aspect 12> The forming agent according to embodiment 11, wherein the first unsaturated organopolysiloxane and the second unsaturated organopolysiloxane are at least one selected from the group consisting of organopolysiloxanes having vinyl groups, vinyl-terminated organopolysiloxanes, and organopolysiloxanes having vinyl-terminated branched chains. <Aspect 13> The shaping agent according to embodiment 12, wherein the first unsaturated organopolysiloxane and the second unsaturated organopolysiloxane are at least one selected from the group consisting of vinyl-terminated polydimethylsiloxane, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl-terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer, vinyl-terminated diethylsiloxane-dimethylsiloxane copolymer, vinyl methylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, silanol-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, vinyl methylsiloxane homopolymer, vinyl T-structure polymer, vinyl Q-structure polymer, monovinyl-terminated polydimethylsiloxane, vinyl methylsiloxane terpolymer, and vinyl methoxysilane homopolymer. <Aspect 14> The forming agent according to any one of embodiments 11 to 13, wherein the first hydride-functionalized polysiloxane and the second hydride-functionalized polysiloxane are organopolysiloxanes that are hydroxylated at the non-terminal and / or terminal ends. <Aspect 15> The forming agent according to embodiment 14, wherein the first hydride-functionalized polysiloxane and the second hydride-functionalized polysiloxane are at least one selected from the group consisting of hydride-terminated polydimethylsiloxane, hydride-terminated polyphenyl-(dimethylhydrosiloxy)siloxane, hydride-terminated methylhydrosiloxane-phenylmethylsiloxane copolymer, trimethylsiloxy-terminated methylhydrosiloxane-dimethylsiloxane copolymer, polymethylhydrosiloxane, trimethylsiloxy-terminated polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer, and methylhydrosiloxane-phenyloctylmethylsiloxane terpolymer. <Aspect 16> The forming agent according to any one of embodiments 11 to 15, wherein at least one of the first agent and the second agent comprises at least one selected from the group consisting of fibers, pigments, dyes, thickeners, ultraviolet absorbers, and fillers. <Aspect 17> A kit in which the first agent and the second agent described in any of embodiments 11 to 16 are contained in separate containers, or contained separately in each compartment of a container having two or more compartments. <Aspect 18> A method of using a forming agent as described in any one of the embodiments 11 to 16, After applying the first agent to the body surface to form a first agent layer, the second agent is applied on the first agent layer and crosslinked to form a body correction film. After applying the second agent to the body surface to form a second agent layer, the first agent is applied on the second agent layer and crosslinked to form a body correction film, or After mixing the first agent and the second agent to prepare a mixture, the mixture is applied to the body surface and crosslinked to form a body correction film. How to use. <Aspect 19> Before applying the first agent, the second agent, or the mixture to the body surface, apply a cosmetic to the body surface. The first agent is applied to the body surface to form a first agent layer, a cosmetic is applied on the first agent layer, and then the second agent is applied to cover the cosmetic. The second agent is applied to the body surface to form a second agent layer, a cosmetic is applied on the second agent layer, and then the first agent is applied to cover the cosmetic, or After forming a body correction film, a cosmetic is applied to the film. The method of use described in aspect 18. <Aspect 20> The method of use according to embodiment 19, wherein the cosmetic is a skincare cosmetic, a sunscreen cosmetic, a base cosmetic, a makeup cosmetic, or a cosmetic that combines two or more of the functions of these cosmetics. [Effects of the Invention]

[0010] According to this disclosure, a second agent for a coating-type body corrective film-forming agent can be provided that can shorten the crosslinking reaction time in film formation and improve the durability of the resulting film. [Brief explanation of the drawing]

[0011] [Figure 1] (a) is a schematic diagram showing the state immediately after applying an oil-in-water composition of one embodiment of the present disclosure to the first agent layer, and (b) is a schematic diagram showing the state after oil droplets in the oil-in-water composition have migrated to the surface of the first agent layer. [Figure 2] (a) is a schematic diagram showing the state immediately after applying the oil-based single-phase composition to the first additive layer, and (b) is a schematic diagram showing the state after the catalyst in the oil-based single-phase composition has migrated to the surface of the first additive layer. [Figure 3] (a) is a schematic diagram showing the state immediately after the water-in-oil composition is applied to the first agent layer, and (b) is a schematic diagram showing the state after the catalyst in the water-in-oil composition has migrated to the surface of the first agent layer. [Modes for carrying out the invention]

[0012] The embodiments of this disclosure will be described in detail below. This disclosure is not limited to the embodiments described below, and can be implemented in various ways within the scope of the essence of the invention.

[0013] The oil-in-water composition of this disclosure is an oil-in-water composition comprising a dispersion medium containing water and oil droplets dispersed in the dispersion medium, wherein the oil droplets contain oil and a catalyst as a crosslinking component, and is used as a second agent in a coating-type body correcting film-forming agent comprising a first agent containing a crosslinking reactive component that constitutes a body correcting film and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component.

[0014] Although not limited by principle, when the oil-in-water composition of this disclosure is used as the second agent in a coating-type body corrective film-forming agent, the principle of action by which such composition can shorten the crosslinking reaction time in film formation and improve the durability of the resulting film is as follows.

[0015] The catalyst, acting as a crosslinking component in the second agent, is typically contained within the oil. Possible forms in which the catalyst is contained within the oil include, for example, the oil-in-water composition shown in Figure 1(a), the single-phase oil shown in Figure 2(a), and the water-in-oil composition shown in Figure 3(a).

[0016] The coating-type body correction film (sometimes referred to as "film") in this disclosure is formed, for example, by contact of a catalyst with a layer containing an unsaturated organopolysiloxane and a hydride-functionalized polysiloxane, which are crosslinking reactive components constituting the body correction film, thereby promoting a crosslinking reaction between the unsaturated organopolysiloxane and the hydride-functionalized polysiloxane.

[0017] The inventors have found that the contact of this catalyst differs depending on the dosage form of the second agent, affecting the crosslinking reaction time in film formation and resulting in differences in the durability of the resulting film. The effects of the crosslinking reaction time in film formation and the durability of the film are described in detail below with reference to Figures 1 to 3.

[0018] For example, when the first agent is applied to the skin, a first agent layer 12 is formed, as shown in Figure 1(a). When the second agent is applied to this first agent layer 12 to form a second agent layer 14, it is thought that immediately after the formation of the second agent layer 14, the oil droplets in the second agent layer are dispersed within the second agent layer. Furthermore, since the first agent layer 12, which contains an unsaturated organopolysiloxane and / or a hydride-functionalized polysiloxane, is lipophilic and has a superior affinity for oil 17 compared to the aqueous phase 18, the oil droplets in the second agent layer are more likely to migrate to the surface of the first agent layer and spread out to blend in, as shown in Figure 1(b), rather than being dispersed within the second agent layer. As a result, it is thought that the catalyst 16 in the oil droplets is more likely to come into contact with the first agent layer 12.

[0019] On the other hand, when the second agent is in the form of a single oil phase or a water-in-oil type, as shown in Figures 2(b) and 3(b), even if the second agent is applied to the first agent layer 22 and 32, unlike in the case of an oil-in-water type, it is thought that the transfer of catalysts 26 and 36 dispersed in the oil 27 and 37 to the first agent layer 22 and 32 is unlikely to occur. As a result, it is thought that most of the catalysts 26 and 36 in the second agent layer 24 and 34 remain dispersed within the second agent layer 24 and 34, that is, they remain in a state that does not contribute to the crosslinking reaction.

[0020] As described above, we believe that the oil-in-water formulation allows the catalyst, as a crosslinking component, to migrate more easily to the surface of the first agent layer compared to the single-phase oil and water-in-oil formulations, thus shortening the crosslinking reaction time during film formation. Furthermore, we believe that the catalyst incorporated into the second agent is used more effectively in the crosslinking reaction with the oil-in-water formulation, resulting in a higher crosslinking density in the film and improved durability of the resulting film.

[0021] The definitions of terms used in this disclosure are as follows:

[0022] In this disclosure, “body corrective coating” means a coating intended to exhibit a natural skin appearance when formed on the skin of a subject. Here, “natural skin appearance” means that, when applied to skin, the body corrective coating exhibits properties similar to or identical to at least one selected from the appearance, feel, and texture of actual skin, for example, that the coated skin may exhibit the physical properties (e.g., elasticity and hardness) of actual (e.g., current) skin.

[0023] In this disclosure, “body correction” means improving a body or skin defect visually and / or tactilely by masking, covering, or concealing a body or skin defect of a person, but does not include methods of surgery, treatment, or diagnosis of a person. Here, “body defect” can mean, for example, any part of the person’s body that the person perceives as a blemish or scar, or that a person skilled in the art, such as a dermatologist, esthetician, or orthopedic surgeon, would consider to be a blemish or scar. “Body defect” includes skin defects and looseness of the body’s soft tissues (e.g., loose or sagging skin, looseness of breasts, buttocks, abdomen, jaw, neck, etc.). “Skin defect” also includes any of these items on the person’s skin that the person perceives as a blemish or scar. Examples of skin defects include flame nevi or nevus (e.g., simple hemangioma or midline flame nevi), melasma, wrinkles, age spots, acne, moles, scars, tattoos, birthmarks, skin deformities, nevi, sunburn, aging, uneven skin tone, sagging skin, rough skin, hyperpigmentation, enlarged pores, tubular dilation, redness, oiliness, cellulite, stretch marks, or loss of skin elasticity.

[0024] In this disclosure, "oil-in-water composition" refers to a composition in which oil droplets are dispersed in a dispersion medium containing water. Such compositions may include, for example, a composition in which oil droplets are forcibly dispersed in a dispersion medium containing water by shaking a liquid that has been separated into water and oil, and an emulsified composition in which oil droplets are dispersed in a dispersion medium containing water by incorporating an emulsifier.

[0025] In this disclosure, “viscosity” refers to a measure of the resistance of a fluid being deformed by either shear stress or tensile stress. For example, the viscosity of the first and second components in a coating-type body correction film-forming agent affects the thickness, ductility, and uniformity and / or homogeneity of the layer formed on the substrate. Viscosity can be expressed as dynamic viscosity (also known as absolute viscosity, typical units being Pa·s, poise, P, cP) or kinematic viscosity (typical units being cm). 2The viscosity can be reported as one of the following: / s, Stoke, St, or cst. This kinematic viscosity is the dynamic viscosity divided by the density of the measured fluid. The viscosity range of the components disclosed herein is generally provided by the supplier of each component as a unit of kinematic viscosity (e.g., cst) measured using a rheometer or Cannon-Fenske tube viscometer, although the viscosity of a fluid can also be measured using, for example, a rheometer (e.g., a linear shear rheometer or a dynamic shear rheometer) or a viscometer (a viscometer, also called a capillary viscometer or rotational viscometer).

[0026] In this disclosure, the term "crosslinking" also includes the concept commonly referred to as "hardening."

[0027] In this disclosure, "body surface" means the surface of the skin of the body.

[0028] 《Oil-in-water composition》 The oil-in-water composition of this disclosure (sometimes simply referred to as "the composition") can be used as the second agent of a coating-type body corrective film-forming agent comprising a first agent containing a crosslinking reactive component that constitutes a body corrective film and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component, thereby shortening the crosslinking reaction time in film formation. For example, when the second agent containing a catalyst is applied to a first agent layer containing an unsaturated organopolysiloxane and a hydride-functionalized polysiloxane, which are crosslinking reactive components that constitute a body corrective film, the crosslinking reaction time can be within 2 minutes, within 1 minute 30 seconds, within 1 minute, within 50 seconds, or within 40 seconds. There is no particular limit to the lower limit of such crosslinking reaction time; for example, it can be 1 second or more, 5 seconds or more, or 10 seconds or more. Here, "crosslinking reaction time" refers to the time from the moment the catalyst is brought into contact with the unsaturated organopolysiloxane and hydride-functionalized polysiloxane until the surface of the film formed by the body-correcting film-forming agent hardens and the film is no longer damaged when touched with a finger.

[0029] The oil-in-water compositions of this disclosure can improve the durability of the resulting film. Such durability can be evaluated by the presence or absence of defects such as peeling or damage to the film immediately after formation. Films prepared using the oil-in-water compositions of this disclosure may, upon visual inspection, exhibit only slight peeling and / or damage, or no peeling or damage at all.

[0030] The durability of the resulting film can also be evaluated by an abrasion resistance test described later. Films prepared using the oil-in-water composition of this disclosure can achieve a number of cycles before damage occurs in an abrasion resistance test of 5 or more, 7 or more, 10 or more, 12 or more, 15 or more, 17 or more, or 20 or more. There is no particular upper limit to such a number, but for example, it can be 200 or less, 150 or less, or 100 or less.

[0031] In some embodiments, the oil-in-water compositions of the present disclosure exhibit excellent emulsifying properties. Emulsifying properties can be evaluated by the uniformity of the emulsified particles (oil droplets) in the oil-in-water composition, that is, by the variation in the particle size of the emulsified particles. The oil-in-water compositions of the present disclosure can have a variation in the particle size of the emulsified particles (oil droplets) of 10 μm or less, 8 μm or less, or 5 μm or less. There is no particular limit to the lower limit of such variation; for example, it can be no variation (0 μm), greater than 0 μm, 0.5 μm or more, or 1 μm or more. Here, the particle size of the emulsified particles is the value observed with an optical microscope.

[0032] <Dispersion medium> The dispersion medium in the oil-in-water composition of this disclosure contains water.

[0033] (water) There are no particular restrictions on the amount of water to be added. For example, from the viewpoint of usability, crosslinking reactivity, etc., the amount of water can be 15% or more by mass, 20% or more by mass, 30% or more by mass, 40% or more by mass, 50% or more by mass, 60% or more by mass, 70% or more by mass, or 80% or more by mass, relative to the total amount of the composition. Alternatively, it can be 90% or less by mass, 80% or less by mass, 70% or less by mass, 60% or less by mass, or 50% or less by mass.

[0034] The water that can be used in the oil-in-water composition of this disclosure is not particularly limited, but for example, water used in cosmetics or quasi-drugs can be used. For example, deionized water, distilled water, ultrapure water, and tap water can be used.

[0035] <Oil drop> In an oil-in-water composition, the oil droplets, which are the oil phase or dispersed phase, contain oil and a catalyst as a crosslinking component.

[0036] (Oil content) There are no particular restrictions on the amount of oil blended. For example, from the viewpoint of usability, crosslinking reactivity, etc., the amount of oil can be 0.01% by mass or more, 0.03% by mass or more, 0.05% by mass or more, 0.07% by mass or more, 0.1% by mass or more, 0.3% by mass or more, 0.5% by mass or more, 0.7% by mass or more, 1% by mass or more, 3% by mass or more, 5% by mass or more, 7% by mass or more, 10% by mass or more, 15% by mass or more, or 20% by mass or more, and it can also be 50% by mass or less, 40% by mass or less, 30% by mass or less, 20% by mass or less, 15% by mass or less, or 10% by mass or less.

[0037] There are no particular restrictions on the oil content, and examples include liquid oils and fats, solid oils and fats, waxes, hydrocarbon oils, silicone oils, and polar oils. The oil content can be used alone or in combination of two or more types. Among these, silicone oil is preferred from the viewpoint of affinity with the first agent layer formed by the first agent described later. There are no particular restrictions on the proportion of silicone oil in the oil content, and for example, it can be 50% by mass or more, 60% by mass or more, 70% by mass or more, 80% by mass or more, or 90% by mass or more, based on the total amount of oil content. There are no particular restrictions on the upper limit of such a proportion, but for example, it can be 100% by mass or less, less than 100% by mass, 98% by mass or less, or 95% by mass or less.

[0038] a. First unsaturated organopolysiloxane The compositions of this disclosure may include, as an oil component, a first unsaturated organopolysiloxane, which is a type of silicone oil. The first unsaturated organopolysiloxane can function as a constituent material of a film, and can also function as a dispersant for a catalyst.

[0039] The first unsaturated organopolysiloxane is not particularly limited, and examples include one or more organopolysiloxanes having at least two carbon-carbon double bonds or at least one carbon-carbon triple bond in the molecule. Preferably, such unsaturated organopolysiloxanes include one or more organopolysiloxanes having, on average, at least two alkenyl functional groups and a viscosity of 10,000 to 2,000,000 cst at 25°C. Hereinafter, "carbon-carbon double bond" and "carbon-carbon triple bond" may be simply referred to as "double bond" and "triple bond." The first unsaturated organopolysiloxane can be used alone or in combination of two or more.

[0040] Such organopolysiloxanes may contain double or triple bonds in the terminal units of the polymer, in the non-terminal monomer units of the polymer, or in a combination thereof, with particular preference for containing them in the non-terminal monomer units of the polymer.

[0041] In one embodiment, the double bond-containing monomer units in the organopolysiloxane may be separated on average by 40 monomer units or more, 200 monomer units or more, 400 monomer units or more, 1,000 monomer units or more, or 2,000 monomer units or more.

[0042] In one embodiment, the amount of double-bond or triple-bond-containing monomer units in the organopolysiloxane having a double-bond or triple-bond can be, for example, 0.01% by mass or more, or 0.03% by mass or more, and 2% by mass or less, or 0.6% by mass or less.

[0043] In some embodiments, the vinyl equivalent of an organopolysiloxane having double or triple bonds can be, for example, 0.005 or more or 0.01 or more per kilogram, and 0.5 or less or 0.25 or less. The approximate molar amount of double or triple bonds in the organopolysiloxane can be calculated based on the average molecular weight of the organopolysiloxane. Herein, the average molecular weight or molecular mass of each component disclosed herein is generally provided by the supplier of each component and can be expressed in units of Daltons (Da) or equivalent g / mol.

[0044] In one embodiment, the first unsaturated organopolysiloxane can have a viscosity of 10,000 to 2,000,000 cst at 25°C. The lower limit of such viscosity is preferably 20,000 cst or more, 40,000 cst or more, 60,000 cst or more, 80,000 cst or more, or 100,000 cst or more, and more preferably 125,000 cst or more or 150,000 cst or more. The upper limit of viscosity is preferably 1,000,000 cst or less, 500,000 cst or less, 450,000 cst or less, 400,000 cst or less, 350,000 cst or less, 300,000 cst or less, or 250,000 cst or less, more preferably 200,000 cst or less or 180,000 cst or less, and even more preferably 165,000 cst or less.

[0045] In one embodiment, the first unsaturated organopolysiloxane can have an average molecular weight of 60,000 Da to 500,000 Da. The lower limit of such average molecular weight is preferably 72,000 Da or more, 84,000 Da or more, 96,000 Da or more, or 100,000 Da or more, and more preferably 140,000 Da or more, or 150,000 Da or more. The upper limit of the average molecular weight is preferably 200,000 Da or less, 190,000 Da or less, 180,000 Da or less, or 170,000 Da or less, more preferably 160,000 Da or less, and even more preferably 155,000 Da or less.

[0046] As the first unsaturated organopolysiloxane, for example, at least one unsaturated organopolysiloxane selected from the group consisting of organopolysiloxanes having vinyl groups, vinyl-terminated organopolysiloxanes, and organopolysiloxanes having vinyl-terminated branched chains can be used.

[0047] Specifically, examples include vinyl-terminated polydimethylsiloxane, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl-terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer, vinyl-terminated diethylsiloxane-dimethylsiloxane copolymer, vinyl-methylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, silanol-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, vinyl methylsiloxane homopolymer, vinyl T-structure polymer, vinyl Q-structure polymer, monovinyl-terminated polydimethylsiloxane, vinyl methylsiloxane terpolymer, and vinyl methoxysilane homopolymer. The first unsaturated organopolysiloxane can be used alone or in combination of two or more. Among these, vinyl-terminated polydimethylsiloxane is preferred, and vinyl dimethicone (divinyldimethicone) is more preferred. In this disclosure, "terminated" refers to either a single-terminated or double-terminated material. When distinguishing between these, for example, "vinyl single-terminated" and "vinyl double-terminated" can be used.

[0048] b. First hydride-functionalized polysiloxane The compositions of this disclosure may include, as an oil component, a first hydride-functionalized polysiloxane, which is a type of silicone oil. The first hydride-functionalized polysiloxane can function as a constituent material of a film.

[0049] There are no particular restrictions on the first hydride-functionalized polysiloxane; for example, the compound of formula 1 below can be used. The first hydride-functionalized polysiloxane can be used alone or in combination of two or more: [ka]

[0050] In formula 1, R1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b are each independently hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl, or C 1-20 alkoxy, and m and n are each independently integers from 10 to 6,000. However, at least one of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b is hydrogen.

[0051] In some embodiments, at least one of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b is hydrogen and the rest are C 1-20 alkyl.

[0052] In some embodiments, at least two of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b are hydrogen (e.g., 2 Si-H units per functionalized hydridopolysiloxane molecule).

[0053] In other embodiments, R1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b At least three of them are hydrogen atoms (for example, three Si-H units per functionalized hydride polysiloxane molecule).

[0054] In some embodiments, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b At least two of them are hydrogen atoms (e.g., two Si-H units per functionalized hydride polysiloxane molecule), and the rest are C 1-20 It is alkyl.

[0055] In other embodiments, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b At least three of them are hydrogen (e.g., three Si-H units per functionalized hydride polysiloxane molecule), and the rest are C 1-20 It is alkyl.

[0056] In some embodiments, R 4b , R 5b , R 9b and R 10b At least two of them are hydrogen atoms (e.g., two Si-H units per functionalized hydride polysiloxane molecule), and the rest are C 1-20 It is alkyl.

[0057] In other embodiments, R 4b , R5b , R 9b and R 10b At least three of which are hydrogen (e.g., 3 Si-H units per functionalized hydridopolysiloxane molecule), and the rest are C 1-20 alkyl.

[0058] In some embodiments, the sum of m and n is an integer from 10 to 1,300, 10 to 1,100, 10 to 600, 15 to 500, 15 to 400, 20 to 300, 20 to 200, 25 to 100, 25 to 75, 30 to 50, or 40 to 45.

[0059] In some embodiments, examples of the first hydridofunctionalized polysiloxane include organopolysiloxanes hydrogenated at non-terminal and / or terminal positions, and are composed of one or more organopolysiloxanes having at least two Si-H units in the molecule. Preferably, examples include one or more organopolysiloxanes having an average of at least two Si-H units and a viscosity of 2 to 100,000 cst at 25°C.

[0060] In one embodiment, the organopolysiloxane having Si-H units may contain such Si-H units in the terminal units of the polymer, in the non-terminal monomer units of the polymer, or in combinations thereof. Among these, it is preferable to contain the Si-H units in the non-terminal monomer units of the polymer. In this case, the first hydridofunctionalized polysiloxane may be alkyl-terminated. For example, in Formula 1, R 2b and R 7b One or both of which may be C 1-20 alkyl.

[0061] In one embodiment, in Formula 1, one, two, three, four, five, or six of R 1b , R 2b , R 3b , R 6b , R 7b and R 8b may be C 1-20 alkyl.

[0062] In one embodiment, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b and R 10b These are C 1-20 Alkyl, for example, C1 alkyl (for example, methyl), R 9b It may be hydrogen.

[0063] In one embodiment, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b and R 9b These are C 1-20 Alkyl, for example, C1 alkyl (for example, methyl), R 10b It may be hydrogen.

[0064] In one embodiment, the Si-H-containing monomer units in the organopolysiloxane may be separated on average by 1 monomer unit or more, 2 monomer units or more, 5 monomer units or more, 10 monomer units or more, 20 monomer units or more, 40 monomer units or more, 200 monomer units or more, 400 monomer units or more, 1,000 monomer units or more, or 2,000 monomer units or more.

[0065] In one embodiment, the amount of Si-H-containing monomer units in the organopolysiloxane having Si-H units can be 0.003% by mass or more, 0.01% by mass or more, 0.1% by mass or more, 1% by mass or more, 3% by mass or more, 5% by mass or more, 10% by mass or more, 20% by mass or more, or 26% by mass or more, and can also be 50% by mass or less, 45% by mass or less, 40% by mass or less, 35% by mass or less, 30% by mass or less, or 27% by mass or less.

[0066] In one embodiment, the Si-H content of the organopolysiloxane having Si-H units can be 0.1 mmol / g or more, 0.5 mmol / g or more, 1 mmol / g or more, 2 mmol / g or more, 3 mmol / g or more, or 4 mmol / g or more, and can be 20 mmol / g or less, 10 mmol / g or less, 9 mmol / g or less, 8 mmol / g or less, 7 mmol / g or less, 6 mmol / g or less, or 5 mmol / g or less. The approximate molar amount of Si-H units in the organopolysiloxane can be calculated based on the average molecular weight of the organopolysiloxane.

[0067] In one embodiment, the first hydride-functionalized polysiloxane can have a viscosity of 2 to 500,000 cst at 25°C. The lower limit of such viscosity is preferably 3 cst or more, 4 cst or more, 5 cst or more, 10 cst or more, 12 cst or more, 15 cst or more, 20 cst or more, 25 cst or more, or 30 cst or more, and more preferably 40 cst or more. The upper limit of viscosity is preferably 200,000 cst or less, 100,000 cst or less, 50,000 cst or less, 20,000 cst or less, 10,000 cst or less, 5,000 cst or less, 2,000 cst or less, or 1,000 cst or less, and more preferably 500 cst or less. The viscosity of the hydride-functionalized polysiloxane is preferably in the range of 45 to 100 cst, or 45 to 50 cst, at 25°C.

[0068] In one embodiment, the hydride-functionalized polysiloxane can have an average molecular weight of 400 to 500,000 Da. The lower limit of such average molecular weight is preferably 500 Da or more, 800 Da or more, 900 Da or more, 1,000 Da or more, 1,200 Da or more, 1,400 Da or more, 1,600 Da or more, 1,800 Da or more, 2,000 Da or more, or 2,200 Da or more, and more preferably 2,300 Da or more. The upper limit of the average molecular weight is preferably 250,000 Da or less, 140,000 Da or less, 100,000 Da or less, 72,000 Da or less, 62,700 Da or less, 60,000 Da or less, 50,000 Da or less, 49,500 Da or less, 36,000 Da or less, 28,000 Da or less, 25,000 Da or less, 20,000 Da or less, 15,000 Da or less, 10,000 Da or less, 5,000 Da or less, or 4,000 Da or less, and more preferably 2,500 Da or less.

[0069] The first hydride-functionalized polysiloxane is not limited to the following, but can be at least one selected from the group consisting of hydride-terminated polydimethylsiloxane, hydride-terminated polyphenyl-(dimethylhydrosiloxy)siloxane, hydride-terminated methylhydrosiloxane-phenylmethylsiloxane copolymer, trimethylsiloxy-terminated methylhydrosiloxane-dimethylsiloxane copolymer, polymethylhydrosiloxane, trimethylsiloxy-terminated polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer, and methylhydrosiloxane-phenyloctylmethylsiloxane terpolymer. Among these, hydride-terminated polydimethylsiloxane is preferred, and hydrogen dimethicone is more preferred.

[0070] c. Other silicone oils Other silicone oils besides the first unsaturated organopolysiloxane and the first hydride-functionalized polysiloxane are not particularly limited and can be used, for example, chain-like silicones such as dimethylpolysiloxane (dimethicone), methylphenylpolysiloxane, and methylhydrogenpolysiloxane; and cyclic silicones such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexasiloxane. Other silicone oils can be used alone or in combination of two or more.

[0071] (catalyst) There are no particular restrictions on the catalyst; for example, any substance capable of causing, promoting, or initiating physical and / or chemical crosslinking reactions with unsaturated organopolysiloxanes and hydride-functionalized polysiloxanes, which are crosslinking reactive components constituting the body correction film. The catalyst may or may not undergo permanent physical and / or chemical changes during or at the end of the process.

[0072] The catalysts are not limited to, but can be metal catalysts capable of initiating and / or promoting crosslinking at temperatures below body temperature, such as Group VIII metal catalysts, such as platinum catalysts, rhodium catalysts, palladium catalysts, cobalt catalysts, nickel catalysts, ruthenium catalysts, osmium catalysts, and iridium catalysts, and Group IVA metal catalysts, such as germanium catalysts and tin catalysts. Among these, platinum catalysts, rhodium catalysts, or tin catalysts are preferred. The catalysts can be used alone or in combination of two or more.

[0073] Examples of platinum catalysts include platinum carbonylcyclovinylmethylsiloxane complexes, platinum divinyltetramethyldisiloxane complexes, platinum cyclovinylmethylsiloxane complexes, platinum octanealdehyde / octanol complexes, and other Pt(0) catalysts such as Karlstedt catalysts, platinum-alcohol complexes, platinum-alkoxide complexes, platinum-ether complexes, platinum-aldehyde complexes, platinum-ketone complexes, platinum-halogen complexes, platinum-sulfur complexes, platinum-nitrogen complexes, platinum-phosphorus complexes, platinum-carbon double bond complexes, platinum-carbon triple bond complexes, platinum-imide complexes, platinum-amide complexes, platinum-ester complexes, platinum-phosphate ester complexes, platinum-thiol ester complexes, platinum lone pair complexes, platinum-aromatic complexes, platinum π-electron complexes, and combinations thereof. In particular, at least one selected from the group consisting of platinum carbonylcyclovinylmethylsiloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethylsiloxane complex, and platinum octanealdehyde / octanol complex is preferred.

[0074] Examples of rhodium catalysts include tris(dibutyl sulfide)rhodium trichloride and rhodium trichloride hydrate.

[0075] Examples of tin catalysts include tin(II) octanoate, tin(II) neodecanoate, dibutyltin diisooctylmaleate, di-n-butylbis(2,4-pentanedionate)tin, di-n-butylbutoxychlorotin, dibutyltin dilaurate, dimethyltin dineodecanoate, dimethylhydroxy(oleate)tin, and tin(II) oleate.

[0076] Among these catalysts, platinum catalysts are more preferred, and platinum divinyltetramethyldisiloxane complexes are particularly preferred.

[0077] The amount of catalyst blended in the oil-in-water composition can be adjusted as appropriate according to the required film performance, etc., and there are no particular restrictions. For example, the amount of catalyst blended can be 0.001% by mass or more, 0.005% by mass or more, or 0.010% by mass or more, and can be 1.0% by mass or less, 0.10% by mass or less, or 0.050% by mass or less, relative to the total amount of the composition.

[0078] The catalyst blending ratio to the oil mentioned above can be 0.060% or more, 0.10% or more, 0.50% or more, 1.0% or more, 5.0% or more, 10% or more, 15% or more, or 20% or more, from the viewpoint of shortening the crosslinking reaction time and the durability of the film. There is no particular upper limit to such blending ratios; for example, it can be 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, or 30% or less. Here, the catalyst blending ratio to the oil can be calculated using the following formula 2. However, in calculating the blending ratio, if the oil contains the first unsaturated organopolysiloxane or the first hydride-functionalized polysiloxane mentioned above, the reactive polymers, the first unsaturated organopolysiloxane and the first hydride-functionalized polysiloxane, are excluded from the oil: Blending ratio (%) = (Catalyst amount (g) × 100) / Oil amount (g) ...Formula 2

[0079] In some embodiments, the oil-in-water composition of the present disclosure may, for example, use a platinum complex as a catalyst, in which the mass ratio of the first unsaturated organopolysiloxane to the total amount of platinum in the platinum complex may be less than 200.

[0080] (emulsifier) In some embodiments, the oil-in-water compositions of this disclosure may contain emulsifiers. In this disclosure, an emulsifier refers to an agent having emulsifying properties (surfactant activity), and may also include agents generally referred to as surfactants. Furthermore, an oil-in-water composition containing an emulsifier may be referred to as an oil-in-water emulsion composition.

[0081] There are no particular restrictions on the amount of emulsifier to be added. For example, from the viewpoint of emulsification stability, the amount can be 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, or 0.2% by mass or more, relative to the total amount of the composition. There are no particular restrictions on the upper limit of the amount of emulsifier to be added. For example, from the viewpoint of film durability, the amount of emulsifier to be added is preferably 5% by mass or less, 4% by mass or less, 3% by mass or less, 2% by mass or less, or 1% by mass or less.

[0082] As emulsifiers, for example, anionic, cationic, amphoteric, or nonionic emulsifiers can be used. Emulsifiers can be used alone or in combination of two or more types.

[0083] Specifically, examples of emulsifiers include at least one selected from the group consisting of hydrocarbon surfactants, silicone surfactants, polymer emulsifiers, and amphiphilic powders.

[0084] Examples of hydrocarbon surfactants include polyoxyethylene alkyl ethers, polyoxyethylene steryl ethers, polyoxyethylene fatty acid esters, polyoxyethylene polyhydric alcohol fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, glycol fatty acid esters, glycerin fatty acid esters, sorbitan fatty acid esters, sucrose fatty acid esters, and polyglycerin fatty acid esters.

[0085] Examples of silicone-based surfactants include polyether-modified silicones and alkyl-comodified polyether-modified silicones.

[0086] Among emulsifiers, polymer emulsifiers are preferred from the viewpoint of uniform dispersion (emulsification) of the catalyst in the composition and the storage stability of the catalyst. Compared to general emulsifiers (surfactants), polymer emulsifiers typically have a larger molecular weight and can be intended to be emulsifiers (surfactants) with lower emulsification ability. Polymer emulsifiers may be used in combination with the emulsifiers mentioned above.

[0087] The weight-average molecular weight of a polymer emulsifier can be 500 or more, 700 or more, 1,000 or more, 1,500 or more, or 2,000 or more, from the viewpoint of emulsifying properties, etc. There is no particular upper limit to the weight-average molecular weight of the polymer emulsifier; for example, it can be 1,000,000 or less, 100,000 or less, 10,000 or less, or 5,000 or less. The weight-average molecular weight of the emulsifier is the polystyrene equivalent value obtained by dissolving the emulsifier in N,N-dimethylformamide (DMF) to prepare a 0.5% solution, and then measuring it by GPC (gel permeation chromatography) under the following conditions: Two α-M columns (manufactured by Showa Denko Corporation) were connected in series and used. Eluent: DMF solution of 60 mmol / L H3PO4 and 50 mmol / L LiBr Flow rate: 1.0mL / min Column temperature: 40℃ Detector: RI Calibration curve: Created using polystyrene.

[0088] There are no particular restrictions on the polymer emulsifier, and examples include at least one selected from the group consisting of (acrylates / alkyl(C10-30)) crosspolymer, (ammonium acryloyldimethyltaurate / beheneth-25 methacrylate) crosspolymer, (hydroxyethyl acrylate / sodium acryloyldimethyltaurate) copolymer, PEG-modified crosspolymer / copolymer siloxane, polyether-modified crosspolymer / copolymer siloxane, stearoxyhydroxypropyl methylcellulose, and polyoxyethylene. Among these, (acrylates / alkyl(C10-30)) crosspolymer is preferred from the viewpoint of emulsification stability and storage stability of the platinum catalyst.

[0089] The amount of polymer emulsifier can be 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, or 0.2% by mass or more, relative to the total amount of the composition, from the viewpoint of uniform dispersion (emulsification) of the catalyst in the composition and storage stability of the catalyst. It can also be 5% by mass or less, 4% by mass or less, 3% by mass or less, 2% by mass or less, or 1% by mass or less. From the viewpoint of film durability, the amount of polymer emulsifier is preferably 2% by mass or less.

[0090] The weight-average molecular weight of general emulsifiers (surfactants) other than high-molecular-weight emulsifiers can be less than 500, 450 or less, or 400 or less, and can also be 100 or more, 150 or more, or 200 or more.

[0091] For general emulsifiers (surfactants) other than high-molecular-weight emulsifiers, the HLB can be 2.0 or higher, 3.0 or higher, or 4.0 or higher, and it can also be 10.0 or lower, 9.0 or lower, or 8.0 or lower.

[0092] 《Topical body correction film-forming agent》 The oil-in-water composition of the present disclosure described above can be suitably used as the second agent in a coating-type body corrective film-forming agent comprising a first agent and a second agent. Such a forming agent can form a body corrective film by, for example, applying the first agent to the body surface to form a first agent layer, and then applying the second agent to the first agent layer to crosslink the first agent layer.

[0093] In some embodiments, the coating performance of the coating-type body corrective film-forming agent can be evaluated by viscosity using a Type B viscometer (Shibaura Systems Co., Ltd., Bismetron). The viscosity of the first and second components of the coating-type body corrective film-forming agent of this disclosure immediately after preparation, measured under conditions of 25°C and 60 revolutions / min (rotor No. 3 or No. 4), is, for example, 100 mPa·s or more, 500 mPa·s or more, 1,000 mPa·s or more, 2,000 mPa·s or more, 5,000 mPa·s or more, 7,500 mPa·s or more, 10,000 mPa·s or more, or 15,000 mPa·s or more. It can be set to 1,000,000 mPa·s or less, 750,000 mPa·s or less, 500,000 mPa·s or less, 250,000 mPa·s or less, 200,000 mPa·s or less, 175,000 mPa·s or less, 150,000 mPa·s or less, 125,000 mPa·s or less, 100,000 mPa·s or less, or 80,000 mPa·s or less. In particular, from the viewpoint of smooth application performance and suppression of dripping from the skin, the first and second components of the application-type body corrective film-forming agent preferably have a viscosity of 20,000 mPa·s or less, 15,000 mPa·s or less, or 10,000 mPa·s or less immediately after preparation, and preferably have a viscosity of 3,000 mPa·s or more, 5,000 mPa·s or more, or 7,000 mPa·s or more.

[0094] In some embodiments, the viscosity of the first and second components of the coating-type body corrective film-forming agent of this disclosure, measured at 25°C and 60 revolutions / minute (rotor No. 3), after two weeks is preferably 50,000 mPa·s or less, 30,000 mPa·s or less, or 15,000 mPa·s or less, and preferably 5,000 mPa·s or more, 7,000 mPa·s or more, or 10,000 mPa·s or more, from the viewpoint of smooth application performance and suppression of dripping from the skin.

[0095] In some embodiments, the coating performance of a body correction film can be evaluated, for example, by whether or not the body correction film tears when peeled from the skin. For example, if the tearing of the applied body correction film is 15% or less, 10% or less, or 5% or less of the total, the coating performance can be said to be excellent. There is no particular limit on the lower limit of tearing, but it can be, for example, 0% or more or greater than 0%. In addition, the coating performance can also be evaluated by tensile strength, elongation at break, etc., as described later.

[0096] <First Agent> The first agent constituting the coating-type body corrective film-forming agent of this disclosure comprises at least one selected from the group consisting of a second unsaturated organopolysiloxane and a second hydride-functionalized polysiloxane. However, if the first agent comprises only the second unsaturated organopolysiloxane from the second unsaturated organopolysiloxane and the second hydride-functionalized polysiloxane, the second agent, which is composed of the oil-in-water composition described above, comprises the first hydride-functionalized polysiloxane described above. Furthermore, if the first agent comprises only the second hydride-functionalized polysiloxane from the second unsaturated organopolysiloxane and the second hydride-functionalized polysiloxane, the second agent comprises the first unsaturated organopolysiloxane.

[0097] The first agent may be in an anhydrous form, or in an oil-in-water or water-in-oil form, but from the viewpoint of drying properties and crosslinking properties after application of the first agent to the body surface, it is advantageous for the first agent to be in an anhydrous form. Here, "water-in-oil" refers to a composition in which water droplets are dispersed in a dispersion medium containing oil, and such compositions can include, for example, a composition in which water droplets are forcibly dispersed in an oil-containing dispersion medium by shaking a liquid that has been separated into water and oil, and an emulsified composition in which water droplets are dispersed in an oil-containing dispersion medium by incorporating an emulsifier.

[0098] Anhydrous forms typically do not require preservatives against bacteria or mold, and therefore can be stored for longer periods than emulsions with similar components. Herein, "anhydrous" in this disclosure means not only that the composition does not contain water, but also that the water content is low, i.e., 10% by mass or less, 5% by mass or less, 2% by mass or less, 1% by mass or less, or 0.1% by mass or less.

[0099] Since the first agent is applied to the body surface by application, it is preferable that it has a glass transition temperature below body temperature from the viewpoint of application performance. For example, the glass transition temperature can be 37°C or lower, 25°C or lower, 10°C or lower, or 0°C or lower. There are no particular restrictions on the lower limit of the glass transition temperature, but for example, it can be -30°C or higher, -20°C or higher, or -10°C or higher. Here, "glass transition temperature" refers to the temperature at which the transition from a solid state to a liquid state occurs, and can be measured, for example, using a differential scanning calorimeter (DSC) in accordance with ASTM D3418-03.

[0100] (Second unsaturated organopolysiloxane) As the second unsaturated organopolysiloxane, the same material as the first unsaturated organopolysiloxane described above can be used.

[0101] The amount of the second unsaturated organopolysiloxane in the first agent can be adjusted as appropriate according to the required film performance, etc., and there are no particular restrictions. For example, the amount of the second unsaturated organopolysiloxane can be 5% by mass or more, 10% by mass or more, 20% by mass or more, 30% by mass or more, 35% by mass or more, or 40% by mass or more relative to the entire first agent, and can be 90% by mass or less, 80% by mass or less, 70% by mass or less, 60% by mass or less, 50% by mass or less, or 45% by mass or less.

[0102] (Second hydride-functionalized polysiloxane) As the second hydride-functionalized polysiloxane, the same material as the first hydride-functionalized polysiloxane described above can be used.

[0103] The amount of the second hydride-functionalized polysiloxane in the first agent can be adjusted as appropriate according to the required film performance, etc., and there are no particular restrictions. For example, the amount of the second hydride-functionalized polysiloxane can be 1% by mass or more, 3% by mass or more, or 5% by mass or more relative to the total amount of the first agent, and can be 75% by mass or less, 60% by mass or less, 50% by mass or less, 40% by mass or less, 30% by mass or less, 20% by mass or less, or 10% by mass or less.

[0104] (Other polymers) The first agent may optionally contain other polymers other than the second unsaturated organopolysiloxane and the second hydride-functionalized polysiloxane. These other polymers may be used alone or in combination of two or more.

[0105] In one embodiment, the other polymer can have a viscosity of 0.7 cst to 50,000 cst at 25°C. The lower limit of such viscosity can be 1 cst or more, 6 cst or more, 10 cst or more, 20 cst or more, 50 cst or more, 100 cst or more, 200 cst or more, 300 cst or more, 400 cst or more, 750 cst or more, 1,000 cst or more, 1,500 cst or more, 2,000 cst or more, 2,500 cst or more, 3,000 cst or more, 3,500 cst or more, or 4,000 cst or more. The upper limit of viscosity can be 45,000 cst or less, 40,000 cst or less, 35,000 cst or less, 30,000 cst or less, 25,000 cst or less, 20,000 cst or less, 15,000 cst or less, 12,000 cst or less, 10,000 cst or less, 5,000 cst or less, 4,000 cst or less, 2,000 cst or less, 1,500 cst or less, or 1,000 cst or less.

[0106] In one embodiment, the other polymer may have an average molecular weight of 180 Da to 80,000 Da. The lower limit of such average molecular weight can be 500 Da or more, 800 Da or more, 1,500 Da or more, 3,000 Da or more, 6,000 Da or more, 9,400 Da or more, 10,000 Da or more, 15,000 Da or more, 20,000 Da or more, 30,000 Da or more, 40,000 Da or more, 50,000 Da or more, 55,000 Da or more, 60,000 Da or more, or 62,000 Da or more. The upper limit of the average molecular weight can be 75,000 Da or less, 70,000 Da or less, 65,000 Da or less, or 63,000 Da or less.

[0107] Other polymers that are preferable include one or more organopolysiloxanes having, on average, at least one alkenyl functional group and a viscosity of 0.7 to 50,000 cst at 25°C.

[0108] Specifically, other polymers include, for example, vinyl-terminated polydimethylsiloxane, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl-terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer, vinyl-terminated diethylsiloxane-dimethylsiloxane copolymer, vinylmethylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, and silanol-terminated vinylmethylsiloxane-dimethylsiloxane copolymer. At least one selected from xan copolymers, vinyl-terminated vinyl rubber, vinyl methylsiloxane homopolymers, vinyl T-structure polymers, vinyl Q-structure polymers, unsaturated organic polymers (e.g., unsaturated fatty alcohols, unsaturated fatty acids, unsaturated fatty esters, unsaturated fatty amides, unsaturated fatty urethanes, unsaturated fatty ureas, ceramides, crocetin, lecithin, and sphingosine), monovinyl-terminated polydimethylsiloxanes, vinyl methylsiloxane terpolymers, vinyl methoxysilane homopolymers, vinyl-terminated polyalkylsiloxane polymers, and vinyl-terminated polyalkoxysiloxane polymers can be used. Among these, vinyl-terminated polydimethylsiloxanes are preferred, and divinyldimethicone and 1,3-divinyltetramethyldisiloxane are more preferred.

[0109] The amount of other polymers in the first agent can be adjusted as appropriate according to the required film performance, etc., and there are no particular restrictions. For example, the amount of other polymers can be 0.01% by mass or more, 0.1% by mass or more, 0.3% by mass or more, or 0.5% by mass or more relative to the entire first agent, and can be 20% by mass or less, 15% by mass or less, or 10% by mass or less.

[0110] <Second unsaturated organopolysiloxane, second hydride-functionalized polysiloxane, and functional group ratios in other polymers> In one embodiment, the molar ratio of the Si-H functional group derived from the second hydride-functionalized polysiloxane to the alkenyl functional group derived from the second unsaturated organopolysiloxane is preferably 60:1 to 1:5, and more preferably 45:1 to 15:1.

[0111] In one embodiment, the molar ratio of the Si-H functional group derived from the second hydride-functionalized polysiloxane to the alkenyl functional group derived from the other polymer is preferably 60:1 to 1:5, and more preferably 45:1 to 15:1.

[0112] In one embodiment, the molar ratio of alkenyl functional groups derived from the second unsaturated organopolysiloxane to alkenyl functional groups derived from the other polymer is preferably 100:1 to 1:100, and more preferably 10:1 to 1:10.

[0113] <Second drug> The coating-type body corrective film-forming agent of this disclosure uses the oil-in-water composition of this disclosure described above as a second agent.

[0114] Furthermore, the second agent can similarly incorporate other polymers mentioned above that can be incorporated into the first agent.

[0115] In the second agent, when the first unsaturated organopolysiloxane and other polymers are used, the ratio of their functional groups can be the same as the ratio of functional groups in the second unsaturated organopolysiloxane and other polymers described above.

[0116] <Optional ingredients> The coating-type body corrective film-forming agent of this disclosure may contain various components as appropriate, provided that they do not affect the effects of this disclosure.

[0117] There are no particular restrictions on optional components, but examples include texture modifiers, tack modifiers, spreadability enhancers, diluents, adhesion modifiers, emulsifiers (surfactants), emollients, solvents, film-forming agents, humectants, preservatives, fibers, pigments, dyes, components that thicken the aqueous or oil phase (thickeners), protective colloids, fillers, skin permeability enhancers, optical modifiers, scattering agents, adsorbents, magnetic materials, gas transport modifiers, liquid transport modifiers, pH modifiers, sensitizers, and aesthetic modifiers. Optional components can be used individually or in combination of two or more.

[0118] Examples of fillers include at least one selected from carbon, silver, mica, zinc sulfide, zinc oxide, titanium dioxide, aluminum oxide, clay, chalk, talc, calcite (e.g., CaCO3), barium sulfate, zirconium dioxide, polymer beads, silica (e.g., fumed silica, silicic acid, or anhydrous silica), silica aluminate, and calcium silicate, which may be surface-treated. Such fillers can improve the physical properties (e.g., strength) of the body correction film and can also act as viscosity modifiers. Among these, surface-treated silica, such as silica treated with a surface treatment agent such as hexamethyldisilazane, polydimethylsiloxane, hexadecylsilane, or methacrylatesilane, is preferred as a filler. Fumed silica is also preferred, and fumed silica surface-treated with hexamethyldisilazane, for example, can be suitably used.

[0119] In one embodiment, the filler is 50-500m 2 It can have a specific surface area of ​​1 / g. The specific surface area of ​​the filler is 100 to 350 m². 2 It is preferable that the value be / g, and 135-250m 2 It is more preferable that the concentration is / g. Here, the specific surface area of ​​the filler can be calculated using the BET method.

[0120] In one embodiment, the filler may have an area-circular particle diameter of 1 nm to 20 μm. Preferably, the area-circular particle diameter of the filler is 2 nm to 1 μm, and more preferably 5 nm to 50 nm. Here, the area-circular particle diameter of the filler can refer to the particle diameter when converted to a circular particle having the same area as the projected area of ​​the filler particles observed with a transmission electron microscope, for example. Such an area-circular particle diameter can be defined as the average value of 10 or more particles.

[0121] The amount of filler added can be, for example, 1% by mass or more, 3% by mass or more, or 5% by mass or more, relative to the total amount of the first or second component, and can be 25% by mass or less, 15% by mass or less, or 10% by mass or less.

[0122] From the viewpoint of reinforcing properties of the body correction film, the mass ratio of the total amount of the first and second unsaturated organopolysiloxanes, the first and second hydride-functionalized polysiloxanes, and other polymers to the filler can be 100:1 to 1:1, preferably 50:1 to 2:1, more preferably 15:1 to 3:1, even more preferably 10:1 to 4:1, and particularly preferably 5:1 to 9:1.

[0123] It is preferable that at least one of the optional components, selected from pigments, dyes, and fillers, be incorporated into the first agent. In particular, with regard to pigments and dyes, if they are incorporated into the second agent, when the second agent is applied to the surface to which the first agent is applied, it may harden midway through the process, causing the pigment or dye to localize and potentially resulting in uneven coloring. From the viewpoint of suppressing uneven coloring, it is advantageous to incorporate pigments and dyes into the first agent. Furthermore, pigments, dyes, and fillers may be incorporated into the second agent to the extent that they do not cause uneven coloring, but it is advantageous that they are not included in the second agent.

[0124] In some embodiments, the compositions of the present disclosure may further contain one or more agents with respect to the first and / or second agent. Examples of such agents include cosmetics, therapeutic agents, irritant responsive agents, and drug delivery agents.

[0125] Suitable cosmetic agents include, for example, moisturizers, UV absorbers, skin protectants, skin soothing agents, skin whitening agents, skin glossing agents, skin emollients, skin smoothing agents, skin bleaching agents, skin exfoliants, skin tightening agents, beauty agents, vitamins, antioxidants, cell signaling agents, cell regulators, cell interaction agents, skin sunscreens, anti-aging agents, wrinkle inhibitors, spot reducers, α-hydroxy acids, β-hydroxy acids, and ceramides.

[0126] Suitable therapeutic agents include, for example, pain relievers, analgesics, antipruritic agents, antiacids (e.g., β-hydroxy acids, salicylic acid, benzoyl peroxide), anti-inflammatory agents, antihistamines, corticosteroids, NSAIDs (non-steroidal anti-inflammatory drugs), antiseptics, antibiotics, antibacterial agents, antifungal agents, antiviral agents, antiallergic agents, anti-irritants, insect repellents, phototherapy agents, blood coagulants, antineoplastic agents, immune system enhancers, immune system suppressants, coal tar, anthraline, fluocinonide, methotrexate, cyclosporine, pimecrolimus, tacrolimus, azathioprine, fluorouracil, ceramides, counter-irritants, and skin cooling compounds.

[0127] Suitable agents include, for example, antioxidants, vitamins, vitamin D3 analogs, retinoids, minerals, mineral oils, petrolatum, fatty acids, plant extracts, polypeptides, antibodies, proteins, sugars, humectants, and emollients.

[0128] Instructions for using topical body correction film-forming agents The topical body corrective film-forming agents of this disclosure can be used, for example, for cosmetic or medical purposes. However, the methods of use of the topical body corrective film-forming agents of this disclosure do not include methods of surgery, treatment, or diagnosis of human beings.

[0129] There are no particular limitations on the method of using the coating-type body corrective film-forming agent of this disclosure. For example, a method in which the first agent is applied to the body surface to form a first agent layer, and then the second agent is applied on the first agent layer and crosslinked to form a body corrective film; a method in which the second agent is applied to the body surface to form a second agent layer, and then the first agent is applied on the second agent layer and crosslinked to form a body corrective film; or a method in which the first agent and the second agent are mixed to prepare a mixture, and then the mixture is applied to the body surface and crosslinked to form a body corrective film. From the viewpoint of obtaining a uniform body corrective film with little unevenness, the method of applying the first agent to the body surface to form a first agent layer, and then the second agent is applied on this first agent layer and crosslinked to form a body corrective film is preferred. Here, the materials described above can be used in the same way for the first agent and the second agent.

[0130] This method may be performed in a single step, or it may be repeated multiple times on the formed body correction film.

[0131] In some embodiments, the cosmetic may be applied to the body surface before applying the first agent, the second agent, or a mixture comprising the first and second agents to the body surface; the first agent may be applied to the body surface to form a first agent layer, the cosmetic may be applied on the first agent layer, and then the second agent may be applied to cover the cosmetic; the second agent may be applied to the body surface to form a second agent layer, the cosmetic may be applied on the second agent layer, and then the first agent may be applied to cover the cosmetic; or, a body corrective film may be formed, and then the cosmetic may be applied to the film.

[0132] There are no particular restrictions on what can be used as a cosmetic product. For example, skincare cosmetics such as serums, lotions, and emulsions, sunscreen cosmetics, makeup bases, or makeup cosmetics such as foundations, lip glosses, lipsticks, eyeshadows, and nail polishes, or cosmetics that combine two or more of these functions, can be used.

[0133] Furthermore, in some embodiments, the method of using the topical body corrective film-forming agent of this disclosure can also be used as a cosmetic method. Note that "cosmetic method" means applying the topical body corrective film-forming agent of this disclosure to the body surface to form a body corrective film, thereby beautifying or improving the condition of the body surface, and is distinct from methods of surgery, treatment, or diagnosis of a human being.

[0134] There are no particular restrictions on the method of applying the first or second agent to the body surface, the cosmetic application layer, or the first or second agent layer. For example, methods such as spreading with fingers, spray application, or transfer can be employed.

[0135] Furthermore, when the first and second agents are separated into water and oil, it is preferable to shake them to forcibly create a two-phase system (oil-in-water or water-in-oil) from the viewpoint of shortening the crosslinking reaction time and improving the durability of the coating.

[0136] <Application area> The topical body corrective film-forming agent disclosed herein can be applied to any part of the body, i.e., any part on the body surface. For example, it can be applied as appropriate to the skin surface of the face (lips, eyes, nose, cheeks, forehead, etc.), neck, ears, hands, arms, legs, feet, chest, abdomen, back, etc. Here, skin includes nails, which are formed by the hardening of the keratinized layer of the epidermis.

[0137] Kit equipped with a topical body correction film-forming agent. The coating-type body corrective film-forming agent of this disclosure can be provided as a kit having a first agent and a second agent constituting such a forming agent. In addition to the first agent and the second agent, the kit may also have any other components, such as a component for facilitating the application of the first agent, etc., to the body surface, and the various cosmetics mentioned above.

[0138] Examples of such optional components include instructions for use, brushes, cotton swabs, cutters, scissors, the various cosmetics mentioned above, cleansers for removing the body correction film from the body surface, and mirrors. Here, "instructions for use" can include not only the general instructions for use attached to the kit in document form, but also, for example, instructions printed on the packaging container that houses the kit, or on the packaging container of the tube into which the first agent is injected.

[0139] In one embodiment, to prevent contact between the first and second agents, the kit may contain the agents in separate containers, or in separate containers within each of two or more compartments. Furthermore, these contained agents may be configured to be applied one at a time, or to be mixed together before or during use.

[0140] Body Correction Membrane <Thickness> There are no particular limitations on the thickness of the body correction film prepared using the coating-type body correction film-forming agent of this disclosure described above. For example, it can be adjusted as appropriate considering factors such as breathability, invisibility, compressibility, and occlusion of the skin. The thickness of the body correction film can be, for example, 0.5 μm or more, 1 μm or more, 10 μm or more, 30 μm or more, or 40 μm or more. There are no particular limitations on the upper limit of the thickness, but for example, it can be 150 μm or less, 100 μm or less, 90 μm or less, 80 μm or less, 70 μm or less, 60 μm or less, or 50 μm or less. Here, the thickness can be defined as the average value calculated by measuring the thickness of any part of the body correction film five times using a high-precision digital micrometer (MDH-25MB, manufactured by Mitutoyo Corporation).

[0141] <Performance> Body correction films prepared from the coating-type body correction film-forming agent of this disclosure can yield excellent results in various performance aspects, such as those described below.

[0142] (Adhesive strength) In some embodiments, the resulting body correction film can exhibit good adhesion to the body surface. This adhesion can be evaluated by comparing it to the adhesion of the body correction film applied to a polypropylene substrate. The adhesion of the body correction film on a polypropylene substrate can achieve values ​​of 2 N / m or more, 5 N / m or more, 8 N / m or more, 10 N / m or more, or 15 N / m or more. There is no particular upper limit to the adhesion, but for example, from the viewpoint of peelability from the skin, it can be set to 200 N / m or less, 100 N / m or less, 80 N / m or less, 50 N / m or less, or 30 N / m or less. Here, the adhesion can be measured using an Instron device in accordance with the peel adhesion test of ASTM C794.

[0143] (Tensile strength) In some embodiments, the resulting body correction film can exhibit good tensile strength. The tensile strength of the body correction film can achieve 0.05 MPa or higher, 0.10 MPa or higher, 0.20 MPa or higher, or 0.50 MPa or higher. There is no particular upper limit on the tensile strength, but for example, it can be 5.0 MPa or lower, 3.0 MPa or lower, 2.0 MPa or lower, or 1.0 MPa or lower. Here, the tensile strength can be measured using an Instron device in accordance with the elongation tensile test of ASTM D5083.

[0144] (Elongation at break) In some embodiments, the resulting body correction film can exhibit good elongation at break. The elongation at break of the body correction film can be 25% or more, 50% or more, 100% or more, 200% or more, or 400% or more. There is no particular upper limit to the elongation at break, but for example, it can be 1,500% or less, 1,200% or less, 1,000% or less, 800% or less, or 600% or less. Here, the elongation at break can be measured using an Instron device in accordance with the tensile strength test of ASTM D5083.

[0145] (Oxygen permeability) In some embodiments, the resulting body correction film can exhibit good oxygen permeability. The oxygen permeability of the body correction film is 5 × 10⁻¹⁰ for a 300 μm thick body correction film. -9 cm 3 / (cm 2 ·s) or more, 5×10 -7 cm 3 / (cm 2 • s) or more, or 5 x 10 -5 cm 3 / (cm 2 It is possible to achieve a value of 5 cm or higher. There is no particular limit on the upper limit of oxygen permeability, but for example, 5 cm 3 / (cm 2 ·s) or less, 0.5cm 3 / (cm 2 ·s) or less, 5×10 -2 cm 3 / (cm 2 ·s) or less, 5×10 -3 cm 3 / (cm 2 ·s) or less, or 5 × 10 -4 cm 3 / (cm 2 ·s) can be less than or equal to the specified value. Here, the oxygen permeability can be measured using a Mocon device in accordance with the oxygen gas permeability test for plastic films and sheets of ASTM F2622.

[0146] (Water vapor transmission rate) In some embodiments, the resulting body correction film can exhibit good water vapor permeability. The water vapor permeability of the body correction film is 1 × 10⁻¹⁶ for a body correction film with a thickness of 300 μm. -9 cm 3 / (cm 2 ·s) or more, 1×10 -8 cm 3 / (cm 2 • s) or more, or 1 × 10 -7 cm 3 / (cm 2 It is possible to achieve a value of 1.5 × 10⁻⁶ or higher. There is no particular upper limit on the water vapor transmission rate, but for example, 1.5 × 10⁻⁶ -1 cm 3 / (cm2 ·s) or less, 1.5×10 -2 cm 3 / (cm 2 ·s) or less, 1×10 -4 cm 3 / (cm 2 ·s) or less, 1×10 -5 cm 3 / (cm 2 ·s) or less, or 1 × 10 -6 cm 3 / (cm 2 • s) can be less than or equal to the following. Here, the water vapor transmission rate can be measured using a Mocon device in accordance with the water vapor transmission rate test for plastic films and sheets of ASTM F1249. [Examples]

[0147] The present invention will be explained in more detail below with reference to examples, but the present invention is not limited to these examples. Unless otherwise specified, the amounts of the ingredients are expressed in mass percent.

[0148] Evaluation Test The following tests were conducted using each test sample obtained by the manufacturing method described below, and the results are summarized in Tables 1 to 5.

[0149] <Evaluation test of crosslinking properties of coatings: Shortening of crosslinking reaction time> Under conditions of 25℃±1℃ and 50%±2% relative humidity, approximately 0.1g of the first agent was spread on the skin to form a roughly circular layer of the first agent with a diameter of approximately 4cm. Then, approximately 0.1g of the second agent was applied to the first agent layer with a finger and spread in a circular motion. The crosslinking reaction time of the film was defined as the time from when the second agent came into contact with the first agent layer until the surface of the film hardened and could not be damaged by touch with a finger. The crosslinking properties of the film were evaluated according to the following evaluation criteria. In the evaluation criteria below, evaluations A to C are considered pass, and evaluation D is considered fail: A: The cross-linking reaction time was within 40 seconds. B: The crosslinking reaction time was between 40 seconds and 1 minute. C: The crosslinking reaction time was between 1 minute and 2 minutes. D: The crosslinking reaction time was over 2 minutes.

[0150] <Visual appearance evaluation test of the coating: Durability of the coating on the surface> Under conditions of 25℃±1℃ and relative humidity of 50%±2%, approximately 0.1g of the first agent was spread on the forearm to form a roughly circular layer of the first agent with a diameter of approximately 4cm. Then, approximately 0.1g of the second agent was applied to the first agent layer with a finger, and the second agent was spread in a circular motion with the finger to create a body correction film. The resulting film was visually inspected for any defects such as peeling or damage, and the durability of the film on the skin was evaluated according to the following evaluation criteria. In the following evaluation criteria, A to B ratings are considered passing, and C ratings are considered failing: A: There was no peeling or damage to the coating. B: There was slight peeling or damage to the coating. C: The coating was clearly peeling or damaged.

[0151] <Abrasion resistance evaluation test: Durability of the coating> Approximately 0.1 g of the first agent was spread on the surface of a 3 cm x 10 cm artificial skin (Supplere (trademark): manufactured by Idemitsu Technofine Co., Ltd.) to form a roughly circular layer of the first agent with a diameter of approximately 4 cm. Then, approximately 0.1 g of the second agent was applied to the first agent layer with a finger, and the second agent was spread in a circular motion with the finger to create a body correction film. Next, the artificial skin with the film applied was set in a Crock meter (manufactured by Hanchen), and the film was repeatedly rubbed while a load of 1 N was applied to the film, and the number of rubs until damage to the film occurred was measured. Here, according to the evaluation criteria below, evaluations A to C are considered pass, and evaluation D is considered fail. The number of rubs until damage is indicated in parentheses in the table: A: The number of times the coating was damaged was 20 or more. B: The number of times the coating was damaged was between 10 and 19. C: The number of times the coating was damaged was between 5 and 9. D: The number of times the coating was damaged was four or less.

[0152] <Emulsification evaluation test: Uniformity of emulsion particles> Under conditions of 25°C ± 1°C, the particle size of emulsion particles (oil droplets) immediately after preparation of oil-in-water and water-in-oil compositions was measured using an optical microscope (BX53, OLYMPUS), and the emulsifying properties were evaluated according to the following evaluation criteria. In evaluating emulsifying properties, 10 emulsion particles were arbitrarily selected, the largest and smallest of these were removed, and the particle sizes of the largest and smallest emulsion particles from the remaining 8 were compared to determine the variation in particle size. In the evaluation criteria below, A to B ratings are considered passing, and C ratings are considered failing: A: The variation in particle size of the emulsified particles was within 5 μm. B: The particle size variation of the emulsified particles was between 5 μm and 10 μm. C: The particle size variation of the emulsified particles was greater than 10 μm.

[0153] [Test Example 1: Confirmation of film crosslinking properties and durability due to differences in the dosage form of the second agent] In Test Example 1, the crosslinking properties and durability of the film were investigated based on differences in the dosage form of the second component in a topical body correction film-forming agent. The results are shown in Tables 1 and 2.

[0154] <Method for producing the first agent, which is used together with a single-phase oil-based and water-in-oil type second agent> The first agent was prepared by uniformly mixing 45 parts by mass of 165,000 cst divinyldimethicone as the second unsaturated organopolysiloxane, 10 parts by mass of 45 cst hydrogendimethicone as the second hydride-functionalized polysiloxane, 7.5 parts by mass of silylated silica as a filler, and 37.5 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0155] <Manufacturing method for the first component used together with the oil-in-water type second component> The first agent was prepared by uniformly mixing 30 parts by mass of 165,000 cst divinyldimethicone as the second unsaturated organopolysiloxane, 7 parts by mass of 45 cst hydrogendimethicone as the second hydride-functionalized polysiloxane, 6 parts by mass of silylated silica as a filler, and 57 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0156] <Method for producing a single-phase oil-based second component> Using the formulations shown in Table 1, the second component, consisting of a single oil phase, was prepared by the following method. Here, the numbers shown below correspond to the numbers indicating the components on the left side of the formulations in Table 1.

[0157] (Comparative Example 1) Materials No. 6 and No. 7 were added to a mixture of oils No. 1, No. 3, and No. 4 and mixed uniformly to prepare the oil-only second phase of Comparative Example 1.

[0158] <Method for producing the second component of a water-in-oil composition> The second component of the water-in-oil composition was prepared using the formulation shown in Table 1 by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulation in Table 1.

[0159] (Comparative Example 2) The oil phase parts were prepared by uniformly mixing materials No. 1 to No. 4, No. 6, and No. 7.

[0160] Materials No. 8 to No. 12 were uniformly mixed to prepare the aqueous phase components.

[0161] The aqueous phase component was added to the oil phase component and uniformly mixed to prepare the second component of the water-in-oil composition of Comparative Example 2.

[0162] (Comparative Examples 3-7) The second component of the water-in-oil compositions of Comparative Examples 3 to 7 was prepared in the same manner as in Comparative Example 2, except that the formulation was changed to that shown in Table 1.

[0163] <Method for producing the second component of an oil-in-water composition> The second component of the oil-in-water composition was prepared using the formulations shown in Table 2 by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulations in Table 2.

[0164] (Example 1) Materials No. 1 to No. 4 and No. 7 to No. 9 were uniformly mixed to prepare the aqueous phase component. Then, catalyst No. 5 was added to this aqueous phase component and uniformly mixed to prepare the second component of the oil-in-water composition of Example 1.

[0165] (Examples 2-7) The second component of the oil-in-water compositions of Examples 2-7 was prepared in the same manner as in Example 1, except that the formulation was changed to that shown in Table 2. The emulsifier No. 6 was added during the preparation of the aqueous phase component.

[0166] [Table 1]

[0167] [Table 2]

[0168] <result> The results in Tables 1 and 2 confirm that when the second agent is in an oil-in-water form, the crosslinking reaction time of the coating can be shortened, and the durability of the coating can also be improved.

[0169] A comparison of Example 1 and Example 2 showed that the use of an emulsifier can improve emulsification. A comparison of Examples 5 to 7 showed that, considering the durability of the coating, it is preferable that the amount of emulsifier added be 5.0% by mass or less.

[0170] [Test Example 2: Confirmation of film crosslinking properties and durability due to differences in the emulsifier of the second agent] In Test Example 2, the crosslinking properties and durability of the film were investigated based on differences in the emulsifier of the second component in a coating-type body corrective film-forming agent. The results are shown in Table 3.

[0171] <Manufacturing method for the first agent used together with the second agent> The first agent was prepared by uniformly mixing 20 parts by mass of 165,000 cst divinyldimethicone as the second unsaturated organopolysiloxane, 10 parts by mass of 45 cst hydrogen dimethicone as the second hydride-functionalized polysiloxane, 40 parts by mass of ion-exchanged water, 1 part by mass of sodium chloride, 1 part by mass of 1,3-butylene glycol, 0.5 parts by mass of phenoxyethanol, and 27.5 parts by mass of a mixture of dimethicone and trisiloxane as the oil component.

[0172] <Method for producing the second component of an oil-in-water composition> The second component of the oil-in-water composition was prepared using the formulation shown in Table 3 by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulation in Table 3.

[0173] (Example 8) Materials No. 1 to No. 4 and No. 18 to No. 21 were uniformly mixed to prepare the aqueous phase component. Then, catalyst No. 17 was added to this aqueous phase component and uniformly mixed to prepare the second component of the oil-in-water composition of Example 8.

[0174] (Examples 9-20) The second component of the oil-in-water compositions of Examples 9-20 was prepared in the same manner as in Example 1, except that the formulation was changed to that shown in Table 3.

[0175] [Table 3]

[0176] <result> The results in Table 3 show that, even when using various emulsifiers, when the formulation of the second agent is in the form of an oil-in-water type, the crosslinking reaction time of the coating can be shortened, and the durability of the coating can also be improved.

[0177] [Test Example 3: Confirmation of film crosslinking properties and durability when a high-molecular-weight emulsifier is used as the emulsifier for the second agent] In Test Example 3, the crosslinkability, durability, etc. when a polymer emulsifier was used as the emulsifier of the second agent in the coating-type body correction film-forming agent were examined. The results are shown in Table 4.

[0178] <Manufacturing Method of the First Agent Used Together with the Second Agent> 45 parts by mass of divinyldimethylsilicone with a viscosity of 165,000 cst as the second unsaturated organopolysiloxane, 10 parts by mass of hydrogen dimethylsilicone with a viscosity of 50 cst as the second hydride-functionalized polysiloxane, 10 parts by mass of zinc oxide, and 35 parts by mass of dimethylsilicone with a viscosity of 1.5 cst as the oil component were uniformly mixed to prepare the first agent.

[0179] <Manufacturing Method of the Second Agent of the Oil-in-Water Type Composition> Using the formulation shown in Table 4, the second agent of the oil-in-water type composition was manufactured by the following method. Here, the numbers shown below correspond to the numbers indicating the components on the left side of the formulation in Table 4.

[0180] (Example 21) Materials of No.1 to No.3 and No.13 to No.16 were uniformly mixed to prepare the aqueous phase part. Then, the catalyst of No.12 was added to this aqueous phase part and uniformly mixed to prepare the second agent of the oil-in-water type composition of Example 21.

[0181] (Examples 22 to 33) The second agents of the oil-in-water type compositions of Examples 22 to 33 were prepared in the same manner as in Example 21, except that the formulation in Table 4 was changed. The polymer emulsifiers of No.4 to No.11 were blended during the preparation of the aqueous phase part.

[0182] [Table 4]

[0183] <Results> From the results in Table 4, it was confirmed that even when various polymer emulsifiers were used, when the dosage form of the second agent was in the form of an oil-in-water type, in addition to the crosslinking reaction time of the film being shortened, the durability of the film was also improved.

[0184] From the comparison between Example 21 and Example 22, it was found that the use of the polymer emulsifier can improve the emulsifying property. From the comparison between Examples 24 to 26, considering the durability of the film, it was found that the blending amount of the polymer emulsifier is preferably 2.0% by mass or less.

[0185] 《Test Example 4: Confirmation of the crosslinkability and durability of the film due to the difference in the blending ratio of the catalyst to the oil component in the second agent》 In Test Example 4, the crosslinkability and durability of the film due to the difference in the blending ratio of the catalyst to the oil component in the second agent were examined. The results are shown in Table 5.

[0186] 〈Manufacturing method of the first agent used together with the second agent〉 45 parts by mass of divinyldimethylsilicone with a viscosity of 165,000 cst as the second unsaturated organopolysiloxane, 10 parts by mass of hydrogen dimethylsilicone with a viscosity of 45 cst as the second hydride-functionalized polysiloxane, 7.5 parts by mass of silylated silica as the filler, and 37.5 parts by mass of a mixture of dimethylsilicone and trisiloxane as the oil component were uniformly mixed to prepare the first agent.

[0187] 〈Manufacturing method of the second agent of the oil-in-water type composition〉 Using the formulation shown in Table 5, the second agent of the oil-in-water type composition was manufactured by the following method. Here, the numbers shown below correspond to the numbers indicating the components on the left side of the formulation in Table 5.

[0188] (Example 34) Materials of No. 1 to No. 6, No. 13 and No. 14 were uniformly mixed to prepare the aqueous phase parts.

[0189] Materials of No. 7 and No. 9 were uniformly mixed to prepare the oil phase parts.

[0190] The oil phase parts were added to the aqueous phase parts and uniformly mixed to prepare the second agent of the oil-in-water type composition of Example 34.

[0191] (Examples 35 to 48) The second component of the oil-in-water compositions of Examples 35-48 was prepared in the same manner as in Example 34, except that the formulation was changed to that shown in Table 5.

[0192] [Table 5]

[0193] <result> The results in Table 5 show that when the catalyst is blended at a ratio of 0.060% or higher to the oil, the crosslinking reaction time of the coating can be further shortened, and the durability of the coating can be further improved.

[0194] Examples of prescriptions for topical body correction film-forming agents. The following are examples of formulations of the first and second agents that can be used as the coating-type body corrective film-forming agent of this disclosure, but the coating-type body corrective film-forming agent of the present invention is not limited to these examples. In addition, all of the coating-type body corrective film-forming agents having the first and second agents described in the following formulation examples were able to shorten the crosslinking reaction time in film formation and improve the durability of the resulting film. The above tests were also conducted for the formulation examples shown below, and the results are summarized in Tables 6 to 8. Here, in the abrasion resistance test, if the number of cycles until damage to the film occurred exceeded 100, it is indicated as "100<".

[0195] <Prescription Example A> (First drug) The first agent was prepared by uniformly mixing 20 parts by mass of 165,000 cst divinyldimethicone as the second unsaturated organopolysiloxane, 10 parts by mass of 45 cst hydrogen dimethicone as the second hydride-functionalized polysiloxane, 30 parts by mass of deionized water, 10 parts by mass of sodium chloride, 1 part by mass of 1,3-butylene glycol, 0.5 parts by mass of phenoxyethanol, and 28.5 parts by mass of a mixture of dimethicone and trisiloxane as the oil component.

[0196] (Second drug) Using the formulation shown in Table 6, the second agent of the oil-in-water composition was produced by the following method. Here, the numbers shown below match the numbers of the components on the left side of the formulation in Table 6.

[0197] a. Formulation Example 1 After uniformly mixing the materials of No. 1 to No. 5, No. 9 to No. 12 to prepare the aqueous phase parts, the catalyst of No. 6 was added to this aqueous phase parts and uniformly mixed to prepare the second agent of the oil-in-water composition of Formulation Example 1.

[0198] b. Formulation Examples 2 to 5 Except for changing to the formulation in Table 6, the second agents of the oil-in-water compositions of Formulation Examples 2 to 5 were prepared in the same manner as Formulation Example 1. The oil components of No. 7 and No. 8 were mixed with the catalyst of No. 6 to form the oil phase parts and added to the aqueous phase parts.

[0199]

Table 6

[0200] 〈Formulation Example B〉 (First Agent) 42 parts by mass of divinyldimethylsilicone with 165,000 cst as the second unsaturated organopolysiloxane, 10 parts by mass of hydrogen dimethylsilicone with 50 cst as the second hydride-functionalized polysiloxane, 10 parts by mass of graphene as the filler, and 38 parts by mass of dimethylsilicone as the oil component were uniformly mixed to prepare the first agent.

[0201] (Second Agent) Using the formulation shown in Table 7, the second agent of the oil-in-water composition was produced by the following method. Here, the numbers shown below match the numbers of the components on the left side of the formulation in Table 7.

[0202] a. Formulation Example 6 After uniformly mixing the materials of No. 1 to No. 3, No. 5, No. 6, No. 9, and No. 14 to No. 16 to prepare the aqueous phase parts, the catalyst of No. 8 was added to this aqueous phase parts and uniformly mixed to prepare the second agent of the oil-in-water composition of Formulation Example 6.

[0203] b. Prescription Examples 7-10 The second components of the oil-in-water compositions of formulations 7-10 were prepared in the same manner as formulation example 6, except for the change in formulation shown in Table 7. Materials No. 11-13 were mixed with catalyst No. 8 and added to the aqueous phase as the oil phase component.

[0204] [Table 7]

[0205] <Prescription Example C> (First drug) The first agent was prepared by uniformly mixing 30 parts by mass of 165,000 cst divinyldimethicone as the second unsaturated organopolysiloxane, 7 parts by mass of 45 cst hydrogendimethicone as the second hydride-functionalized polysiloxane, 6 parts by mass of silylated silica as a filler, and 57 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0206] (Second drug) The second component of the oil-in-water composition was prepared using the formulation shown in Table 8 by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulation in Table 8.

[0207] a. Prescription example 11 The aqueous phase parts were prepared by uniformly mixing materials No. 1 to No. 5, No. 7, No. 8, and No. 12 to No. 14.

[0208] The oil phase parts were prepared by uniformly mixing materials No. 6 and No. 9 to No. 11.

[0209] The oil phase component was added to the aqueous phase component and mixed uniformly to prepare the second component of the oil-in-water composition of Formulation Example 11.

[0210] b. Prescription Examples 12-13 The second component of the oil-in-water composition for formulations 12-13 was prepared in the same manner as formulation example 11, except for the change in formulation shown in Table 8.

[0211] [Table 8]

[0212] [Example of a prescription for the first agent of a topical body correction film-forming agent] Tables 9 to 12 show examples of formulations of the first agent that can be used as a topical body corrective film-forming agent according to this disclosure, but the first agent of the topical body corrective film-forming agent of the present invention is not limited to these examples. These formulations can be prepared by conventional methods.

[0213] [Table 9]

[0214] [Table 10]

[0215] [Table 11]

[0216] [Table 12] [Explanation of symbols]

[0217] 10, 20, 30 skin 12, 22, 32 1st agent layer 14, 24, 34 2nd agent layer 16, 26, 36 Catalyst 17, 27, 37 Oil content 18, 38 aqueous phase

Claims

[Claim 1] A dispersion medium containing water, and Oil droplets dispersed in the aforementioned dispersion medium An oil-in-water composition comprising, The oil droplets contain oil and a catalyst as a crosslinking component. Used as the second agent in a coating-type body corrective film-forming agent, comprising a first agent containing a crosslinking reactive component that constitutes a body corrective film and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component, Oil-in-water composition.

Images